10-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-K/A

(Amendment No.2)

(Mark One)


☒	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2021


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO

Commission File Number: 001-36247

Meta Materials Inc.

(Exact Name of Registrant as Specified in its Charter)


Nevada	74-3237581
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

60 Highfield Park Drive Dartmouth, Nova Scotia	B3A 4R9
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (902) 482-5729

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 

Trading
Symbol(s)
 

Name of each exchange
on which registered
 

Common Stock, par value $0.001 per share

MMAT

Nasdaq Capital Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

If securities registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on June 30, 2021, was $1,523,026,255.

The number of shares of Registrant’s Common Stock outstanding as of March 1, 2022 was 284,812,797.

Auditor Firm Id: 85; Auditor Name: KPMG LLP; Auditor Location: Vaughan, Canada


	Page	1

EXPLANATORY NOTE

This Amendment No. 2 to Form 10-K of Meta Materials, Inc., referred to in this report as the "Company”, “META”, "we", "us" or "our", is being filed solely

(i) to correct and update certain information regarding executive compensation set forth in Part III, Item 11, including:

a) correcting the amount of bonus earned by George Palikaras, our President and Chief Executive Officer, in fiscal year 2021, which was understated by $268,459;

b) correcting the amount of option awards granted to Mr. Palikaras and Jonathan Waldern, our former Chief Technology Officer, in fiscal year 2021 from $261,213 and $175,587, respectively, to be $Nil as they were not granted;

c) reclassifying certain compensation earned by Ken Rice, our former Chief Financial Officer and Chief Operating Officer, and Dr. Waldern from bonus to non-equity incentive plan compensation;

d) correcting the amount of other compensation earned by Mr. Rice, which was understated by $19,290, to include medical benefits earned by Mr. Rice;

e) adding the Outstanding Equity Awards at December 31, 2021 table, which was inadvertently omitted from Amendment No. 1 to the Original Filing (as defined below);

f) adding information inadvertently omitted from the 2021 director compensation table, including required footnotes and director compensation for Gregory McCabe, Alexandre Zyngier, Michael J. Graves, and Robert L. Cook, each of whom resigned on June 28, 2021 from the Company’s board of directors and any respective committees thereof to which they belonged at the closing of the reverse merger; and

(ii) to restate Part II, Item 9A, to reflect deficiencies in disclosure controls and procedures identified by the Company’s management related to such errors.

As required by Rule 12b-15, in connection with this Amendment No. 2, the Company’s Principal Executive Officer and Principal Financial Officer are providing new Rule 13a-14 certifications. Because no financial statements have been included in this Amendment No 2, paragraph 3 of the certifications has been omitted. Additionally, because no financial statements are contained within this Amendment No. 2, the Company has not included new certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Except as explicitly set forth herein, this Amendment No. 2 does not purport to modify or update the disclosures in, or exhibits to original Form 10-K (the “Original Filing”) or Amendment No. 1, or to update the Original Filing or Amendment No. 1 to reflect events occurring after the date of such filing.


Page	2

Table of Contents


PART II
Item 9A.	Controls and Procedures	4

PART III
Item 11.	Executive Compensation	7

PART IV
Item 15.	Exhibits, Financial Statement Schedules	12


Page	3

Part II

Item 9A. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

In connection with the Original Filing, management, with the participation of the Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2021.

Based on such evaluation, the Company's management, including the Chief Executive Officer and Chief Financial Officer, have concluded that, due to the material weaknesses in the Company's internal control over financial reporting described below under “Management’s Report on Internal Control over Financial Reporting,” the Company's disclosure controls and procedures were not effective as of December 31, 2021.

In connection with the preparation and filing of this Amendment No. 2, our Chief Executive Officer and Chief Financial Officer re-evaluated the effectiveness of the design and operation of our disclosure controls and procedures, taking into account the errors summarized in the Explanatory Note to, and corrected in Part III, Item 11 of, this Amendment No. 2. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of December 31, 2021, our disclosure controls and procedures were not effective due to the aforementioned material weakness and also due to incomplete corporate records and a lack of effective processes relating to the preparation and review of the compensation disclosures required by Part III, Item 11 of Form 10-K. We are implementing additional operational procedures designed to ensure the effectiveness of our disclosure controls and procedures with respect to future reports that we file with or submit to the SEC under the Exchange Act.

Notwithstanding the foregoing, giving full consideration to the material weaknesses, the Company has concluded that the consolidated financial statements included in the Annual Report on Form 10-K present fairly, in all material respects, the Company’s financial position, the results of its operations and its cash flows for each of the periods presented in conformity with U.S. generally accepted accounting principles.

Management’s Report on Internal Control over Financial Reporting

The Company's management is responsible for establishing and maintaining effective internal control over financial reporting, as such term is defined in Securities Exchange Act Rule 13a‑15(f). The Company’s internal control over financial reporting is a process designed by and under the supervision of the Company's management, including the Company's Chief Executive Officer and Chief Financial Officer, and effected by the Company’s management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with U.S. generally accepted accounting principles. The Company’s management, under the supervision and with the participation of its Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the Company’s internal control over financial reporting as of December 31, 2021, using the criteria set forth in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management concluded that internal control over financial reporting was not effective as of December 31, 2021, due to material weaknesses in internal control over financial reporting, as described further below.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements may not be prevented or detected on a timely basis.

Management determined that it did not maintain effective internal controls over financial reporting due to the existence of the following identified material weaknesses:

•

An ineffective control environment resulting from a lack of the required number of trained financial reporting, accounting, information technology (IT) and operational personnel with the appropriate skills and knowledge and with assigned responsibility and accountability related to the design, implementation, and operation of internal control over financial reporting.

•

The insufficient number of personnel described above contributed to an ineffective risk assessment process necessary to identify all relevant risks of material misstatement and to evaluate the implications of relevant risks on its internal control over financial reporting.

•

An ineffective information and communication process resulting from: (i) insufficient communication of internal control information, including objectives and responsibilities, such as delegation of authority; and (ii) ineffective general IT


Page	4

controls and ineffective controls over information from a service organization, resulting in insufficient controls to ensure the relevance, timeliness and quality of information used in control activities.

•

As a consequence of the above, the Company had ineffective control activities related to the design, implementation and operation of process level and financial statement close controls which had a pervasive impact on the Company's internal control over financial reporting.

•

An ineffective monitoring process resulting from the evaluation and communication of internal control deficiencies, including monitoring corrective actions, not being performed in a timely manner.

These material weaknesses resulted in material misstatements, which were corrected prior to the release of the consolidated financial statements as of and for the year ended December 31, 2021, and also in immaterial misstatements, some of which were corrected prior to the release of the consolidated financial statements as of and for the year ended December 31, 2021. These material weaknesses create a reasonable possibility that a material misstatement to the consolidated financial statements will not be prevented or detected on a timely basis.

In accordance with guidance issued by the SEC, companies are permitted to exclude acquisitions from their final assessment of internal control over financial reporting for the first fiscal year in which the acquisition occurred. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has limited the evaluation of our internal controls over financial reporting to exclude controls, policies and procedures and internal controls over financial reporting of the recently acquired operations of Nanotech Security Corp. (acquired on October 5, 2021). The operations of Nanotech Security Corp. represent approximately 17% of our total assets and 45% of our total revenues for the year ended December 31, 2021.

KPMG LLP, our independent registered public accounting firm, has issued an attestation report on the Company’s internal control over financial reporting, which report expresses an adverse opinion on the effectiveness of internal control over financial reporting.

Plan for Remediation of Material Weaknesses

Management is continuing to evaluate and strengthen the Company's internal controls over financial reporting to ensure that management can routinely prepare our financial statements under GAAP, meet the requirements of the Company's independent auditors and remain in compliance with the SEC reporting requirements. These efforts are time consuming and require significant resource investment that the Company is committed to making.

As of December 31, 2021, the Company is still developing and documenting the full extent of the procedures to implement to remediate the material weaknesses described above, however the current remediation plan includes:

•

Training the newly hired ERP specialist and Supply Chain and Procurement Director.

•

Identifying and hiring additional key positions necessary to support the Company’s initiatives related to internal controls over financial reporting, including but not limited to Technical Accounting, Transactional Accounting, IT Management and Analysts.

•

Hiring consultants to assist with process improvements and control remediation efforts in targeted accounting, IT and operations processes.

•

Continuing on-going testing of policies and procedures implemented in late 2021 to assess their effectiveness.

•

Formalizing its entity-wide risk assessment process, and documenting internal ownership of risk monitoring and mitigation efforts, with improved risk monitoring activities and regular reporting to those charged with governance at an appropriate frequency.

•

Finalize a delegation of authority matrix to enforce desired limits of authority for key transactions, events, and commitments, and communicating these limits of authority to relevant personnel throughout the Company.

Changes in Internal Controls.

Except for the remediation efforts relating to the material weaknesses described above, no changes in the Company's internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the quarter ended December 31, 2021 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.


Page	5

Limitations on Effectiveness of Internal Controls

Management, including the Chief Executive Officer and Chief Financial Officer, does not expect that disclosure controls or internal controls, when effective, will prevent all errors and detect all accounting irregularities. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. In addition, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of accounting irregularities, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake.

Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people. The design of any systems of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of these inherent limitations in a cost-effective control system, misstatements due to errors may occur and not be detected.


Page	6

Part III

Item 11. Executive Compensation.

Compensation of Named Executive Officers

Summary Compensation Table

The following table summarizes the compensation for each of our executive officers (the “Named Executive Officers”) during the fiscal year ended December 31, 2021.


									Non-equity
							Option		Incentive Plan		All Other
		Salary		Bonus			Awards		Compensation		Compensation			Total
Name and Principal Position	Year	($)		($)			($) (1)		($)		($)			($)

George Palikaras	2021		300,558		682,500	(2)		-		-		-			983,058
President/CEO/Director
Kenneth Rice (5)	2021		231,100		200,000	(3)		-		104,850		19,290	(4)		555,240
Chief Financial Officer and Executive Vice President
Jonathan Waldern (6)	2021		238,078		-			-		182,500		-			420,578
Chief Technology Officer
John A. Brda	2021		187,500		1,500,000			-		-		-			1,687,500
Former CEO/Secretary/Director	2020		375,000		-			-		-		-			375,000


(1)	The amounts reported in the Option Awards column represent the grant date fair value of the stock options granted to the named executive officers as of the grant date as computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, not including any estimates of forfeitures. The assumptions used in calculating the grant date fair value of the stock options reported in the Option Awards column are set forth in Note 15 to our financial statements included in our Annual Report on Form 10-K/A for the year ended December 31, 2021 filed with the SEC on March 2, 2022 for option awards in 2021. Note that the amounts reported in this column reflect the accounting cost for these stock options, and do not correspond to the actual economic value that may be received by the named executive officers from the options.
(2)	On July 9, 2021, Mr. Palikaras was awarded a bonus of $300,000 based upon the successful completion of the reverse merger with Torchlight Energy Resources, Inc. ("Torchlight"). On March 28, 2022, Mr. Palikaras was awarded a bonus of $382,500 based on 2021 performance.
(3)	On July 9, 2021, Mr. Rice was awarded a bonus of $200,000 based upon the successful completion of the reverse merger with Torchlight.
(4)	Represents medical expense reimbursement.
(5)	Mr. Rice's employment as our CFO and COO terminated on April 20, 2023.
(6)	Dr. Waldern's employment as our CTO terminated on April 21, 2023.


Page	7

Employment Agreements

George Palikaras

On July 1, 2021, Metamaterial Technologies Canada Inc., or Meta Canada, a wholly owned subsidiary of ours, entered into an executive employment contract with George Palikaras, or the Palikaras Employment Agreement, pursuant to which we agreed to employ Mr. Palikaras as our CEO, effective as of July 1, 2021, for an indefinite term in consideration of an annual base salary of CAD $553,500. Pursuant to the terms and conditions of the Palikaras Employment Agreement, Mr. Palikaras was granted a stock option award with a grant date value of $800,000, subject to the terms of our Amended and Restated Employee Stock Option Plan, and a grant of restricted stock units under our 2021 Equity Incentive Plan with a value of $800,000 (prorated for partial years of employment). In the event that the Palikaras Employment Agreement is terminated, we shall provide Mr. Palikaras with earned but unpaid salary, vacation pay and reimbursement of expenses and any other severance amounts as are required by applicable employment standards legislation.

Kenneth Rice

On December 14, 2020, we entered into an executive employment agreement with Kenneth Rice, or the Rice Employment Agreement pursuant to which we agreed to employ Mr. Rice as our CFO and Executive Vice President, effective as of December14, 2020, for an indefinite term. The Rice Agreement provided for an initial annual base salary of $156,000, scheduled to increase to $216,000 on March 1, 2021. Under the terms of the Rice Agreement, Mr. Rice is eligible to receive a quarterly bonus up to a target of $27,000 based on his achievement of a balanced scorecard, in the sole discretion of our Board of Directors. In the first two years following the effective date of the Rice Employment Agreement, 25% of any quarterly bonus shall be issued in an amount of fully vested stock options. In addition, the Rice Employment Agreement provided for a grant to Mr. Rice of an option to acquire 300,000 shares under our Amended and Restated Employee Stock Option Plan.

In the event Mr. Rice’s employment is terminated by us without Cause or Mr. Rice resigns for Good Reason (as defined in the Rice Employment Agreement) and subject to Mr. Rice signing a release within 60 days of termination, the Rice Employment Agreement provides that Mr. Rice will receive continued payment of his base salary for 6 months; payment of two quarterly bonuses to be made quarterly following the termination date; a prorated amount of the quarterly bonus for the calendar quarter in which the termination occurs based on the date of termination; continued Company benefits, excluding disability coverage, for the severance period, if such benefits are available under the terms of our benefits plans; and six months’ accelerated vesting of the initial option grant described above. If Mr. Rice is terminated for Cause, he will only be entitled to earned but unpaid salary, vacation pay and reimbursement of expenses.

Jonathan Waldern

On December 16, 2020, we entered into an executive employment agreement with Jonathan Waldern, or the Waldern Employment Agreement pursuant to which we agreed to employ Dr. Waldern as our CTO, effective as of December16, 2020, for an indefinite term. The Waldern Employment Agreement provided an initial annual base salary of $150,000, scheduled to increase to $250,000 upon achievement of a public offering milestone specified in the agreement. Pursuant to the Waldern Agreement, Dr. Waldern is eligible to receive a quarterly cash bonus up to a target of $50,000 based on achievement of a balanced scorecard, in the sole discretion of the Company or the Board of Directors. In the first two years of employment, Dr. Waldern is also eligible to receive up to 0.25% per quarter of our then outstanding common stock as fully vested stock options. In addition, the agreement provided for a grant to Dr. Waldern of an option to acquire 1,115,000 shares under our Amended and Restated Employee Stock Option Plan.

In the event Dr. Waldern’s employment is terminated by us without Cause or Dr. Waldern resigns for Good Reason (each as defined in the Waldern Employment Agreement), and subject to Dr. Waldern signing a release within 60 days of termination, the Waldern Employee Agreement provides that Dr. Waldern will receive continued payment of base salary for 6 months; payment of two quarterly bonuses to be made quarterly following the termination date; continued benefits, excluding disability coverage, for a period of twelve (12) months, if such benefits are available under the terms of our benefits plans; and six months’ accelerated vesting of the initial option grant described above.

The Waldern Employment Agreement provides that Dr. Waldern may resign without Good Reason (as defined in the Waldern Employment Agreement) by providing the Company with six months’ advance written notice. During the notice period, Dr. Waldern will be entitled to continue to receive his base salary and benefits, but will not be entitled to quarterly bonuses for any calendar quarter that ends or begins during that 6-month period.


Page	8

John Brda

On July 15, 2020, Torchlight entered into new one-year employment agreements with John Brda, then President and Chief Executive Officer. His previous employment agreement expired in June 2020. Under the new agreement, Mr. Brda continued to receive the same annual salary of $375,000, with 36% of his salary, continuing to accrue unpaid until such time as the Board of Directors believed there is adequate cash for such payment, or as otherwise contemplated in the employment agreement. Mr. Brda was eligible for a bonus at the Compensation Committee’s discretion. Mr. Brda’s agreement provided that upon a “change of control” in the company (as defined in the agreement), Mr. Brda would be paid in one lump sum any amounts owed to the employee under the agreement that are accrued and unpaid plus his salary that would be earned through the end of the term of the agreement. The employment agreement has a covenant not to compete and provides for expense reimbursement, four weeks of vacation and certain other benefits.

Additionally, as part of his employment compensation, the Compensation Committee granted Mr. Brda an option to purchase a total of up to 2,250,000 shares of common stock, including up to 375,000 shares at an exercise price of $0.50 per share and up to 1,875,000 shares at an exercise price of $1.00 per share. The option was granted under Torchlight’s Amended and Restated 2015 Stock Option Plan. The terms of the option provided that the option would vest upon either (a) the approval by shareholders of a change of control occurring prior to July 15, 2021, or (b) the company entering into a letter of intent with a third party prior to July 15, 2021 that contemplates a change of control, and the change of control transaction closes with that third party (or an affiliate(s) of that third party) at a date not later than July 15, 2022; subject, however, to acceleration and earlier vesting of all of the option in the event of (i) the termination of employment by the employee for “good reason” under his employment agreement or (ii) a determination of the Compensation Committee, at its discretion. In the event of the death or disability of the employee prior to vesting or if the company terminates the employee’s employment for reasons other than for “cause” under the employment agreement prior to vesting, the option will still vest upon the occurrence of the events described under clauses (a) or (b) above. The option, to the extent such option has not been exercised, will terminate and become null and void on July 15, 2025, if and only if the option vest as described above, or on July 15, 2021, if the option do not vest as described above, subject to the occurrence of the events contemplated under clause (b) above whereby the option would not terminate until July 15, 2022.

Outstanding Equity Awards at December 31, 2021

The following table presents information regarding all outstanding equity awards and held by each of our named executive officers as of December 31, 2021.

Option Awards

Stock Awards

Number of

Number of

Number of

Market Value

Securities

Securities

Shares or

of Shares or

Underlying

Underlying

Units of

Units of

Unexercised

Unexercised

Option

Stock That

Stock That

Options

Options

Exercise

Option

Have Not

Have Not

(#)

(#)

Price

Expiration

Vested

Vested (1)

Name and Principal Position

Exercisable

Unexercisable

($)

Date

(#)

($)

George Palikaras

-

1,476,000

(2)

0.27

23-Mar-30

President/CEO/Director

1,461,240

(3)

3,594,650

Kenneth Rice

553,500

(4)

-

0.27

14-Dec-30

Chief Financial Officer and Executive Vice President

Jonathan Waldern

42,856

(5)

1,542,881

(5)

0.27

14-Dec-30

Chief Technology Officer

John A. Brda

937,500

(6)

-

2.00

15-Jul-25

Former CEO/Secretary/Director

187,500

(6)

-

1.00

15-Jul-25


(1)	Represents the market value of the unvested shares underlying the share awards as of December 31, 2021, based on the closing price of our common shares on such date, as reported on the Nasdaq Capital Market, which was $2.46 per share. These amounts do not reflect the actual economic value that will be realized by the named executive officer upon the vesting of the share awards or the sale of the common stock underlying such share awards.

(2)	Vests annually over two years, beginning on March 23, 2020, subject to the terms, conditions and restrictions of the award agreement governing the grant.


Page	9


(3)	Represents fully vested deferred stock units (“DSUs”), which were granted on March 28, 2013. Each unit is convertible at the option of the holder into one common share upon its settlement; however, DSUs are unable to be settled until the holder ceases to be a service provider to the Company. The holder is entitled to settle all DSUs, including dividends and other adjustments, no later than December 1 of the first calendar year commencing after the time of his termination.
(4)	Fully vested at a grant date of December 14, 2020.
(5)	25% of the shares subject to the option shall vest on the one-year anniversary from the vesting commencement date of December 14, 2020, and thereafter the remaining shares subject to the option shall vest in equal monthly installments over the next 36 months on the same day of the month as the vesting commencement date.
(6)	The options were awarded on July 15, 2020. The Compensation Committee granted Mr. Brda an option to purchase a total of up to 1,125,000 shares of common stock, including up to 187,500 shares at an exercise price of $1.00 per share and up to 937,500 shares at an exercise price of $2.00 per share. The options were granted under our 2015 Stock Option Plan which plan was approved by stockholders on October 26, 2020.

Compensation of Directors

The compensation committee of the Company's board recommends director compensation to its board of directors based on factors it considers appropriate, market conditions and trends and the recommendations of management.


	Fees Earned						Non-Equity		Nonqualified
	And Accrued		Stock		Option		Incentive Plan		Deferred
	in 2021		Awards		Awards		Compensation		Compensation		All Other		Total
Name	($)(3)		($)(1)		($)		($)		Earnings ($)		Compensation ($)		($)

Ram Ramkumar (2) (4)		39,648		79,672		-		-		-		-		119,320
Maurice Guitton (2) (5)		32,148		79,672		-		-		-		-		111,820
Allison Christilaw (2) (6)		32,148		79,672		-		-		-		-		111,820
Steen Karsbo (2) (7)		32,148		79,672		-		-		-		-		111,820
Eric Leslie (2) (8)		32,148		79,672		-		-		-		-		111,820
Ken Hannah (2) (9)		22,500		119,508		-		-		-		-		142,008
Alexandre Zyngier (3)		50,000		-		-		-		-		-		50,000
Robert Lance Cook (3)		50,000		-		-		-		-		-		50,000
Michael Graves (3)		50,000		-		-		-		-		-		50,000
Greg McCabe (3)		-		-		-		-		-		-		-


(1)	Equity awards value comprises of share-based compensation from DSUs valued using the grant date fair value.
(2)	We reimburse our directors for expenses associated with attending meetings of our board of directors and committees of our board of directors. Each director receives cash fees of $11,250, and the chairman of the Board receives cash fees of $15,000, each paid on a quarterly basis in arrears. Before the merger with Torchlight, each director received CAD 3,000 quarterly, which was converted to USD 2,412 based on the exchange rate of CAD 1.2438 per 1 USD. Directors who are also our employees receive no additional compensation for their service as a director. During 2021, 29,508 DSUs were granted to each director as an annual equity awards. Mr. Hannah entitled additional 14,754 DSUs as an initial equity award for newly elected directors.
(3)	Mr. Zyngier, Mr. Cook, Mr. Graves and Mr. McCabe resigned as board members in June 2021 in connection with the closing of our merger with Torchlight. Amount reflects fees paid to each of Mr. Zyngier, Mr. Cook, Mr. Graves and Mr. McCabe through the end of their board service period.
(4)	As of December 31, 2021, Mr. Ramkumar had outstanding options representing the right to purchase of 369,000 shares of common stock, fully vested as of December 31, 2021, at an exercise price of $0.15 per share, and outstanding options representing the right to purchase of 553,500 shares of common stock, of which 184,500 equivalent shares of options vested and are exercisable as of December 31, 2021, at an exercise price of $0.27 per share. Mr. Ramkumar had outstanding DSUs of 29,508 as of December 31, 2021.
(5)	As of December 31, 2021, Mr. Guitton had outstanding options representing the right to purchase of 1,214,197 shares of common stock, of which 845,198 equivalent shares of options vested and are exercisable as of December 31, 2021, at an exercise price of $0.27 per share. Mr. Guitton had outstanding DSUs of 777,618 as of December 31, 2021.
(6)	As of December 31, 2021, Ms. Christilaw had outstanding options representing the right to purchase of 553,500 shares of common stock, of which 184,500 equivalent shares of options vested and are exercisable as of December 31, 2021, at an exercise price of $0.27 per share. Ms. Christilaw had outstanding DSUs of 29,508 as of December 31, 2021.
(7)	As of December 31, 2021, Mr. Karsbo had outstanding options representing the right to purchase of 553,500 shares of common stock, of which 184,500 equivalent shares of options vested and are exercisable as of December 31, 2021, at an exercise price of $0.27 per share. Mr. Karsbo had outstanding DSUs of 29,508 as of December 31, 2021.


Page	10


(8)	As of December 31, 2021, Mr. Leslie had outstanding options representing the right to purchase of 1,083,804 shares of common stock, of which 714,803 equivalent shares of options vested and are exercisable as of December 31, 2021, at an exercise price of $0.27 per share. Mr. Leslie had outstanding DSUs of 29,508 as of December 31, 2021.
(9)	Mr. Hannah had outstanding DSUs of 44,262 as of December 31, 2021.


Page	11

PART IV

Item 15. Exhibits, Financial Statement Schedules.

Exhibit Index


		Incorporated by Reference
Exhibit Number	Exhibit Description	Form	Filing Date	Filed Herewith
1.1.0	Underwriting Agreement, dated February 8, 2021, between Torchlight Energy Resources, Inc. and Roth Capital Partners, LLC	10-K	18-Mar-21
1.2.0	Sales Agreement, dated as of June 16, 2021, by and between Torchlight Energy Resources, Inc. and Roth Capital Partners, LLC	8-K	16-Jun-21
1.2.1	Amended and Restated Sales Agreement, dated as of June 21, 2021, by and between Torchlight Energy Resources, Inc. and Roth Capital Partners, LLC	8-K	21-Jun-21
2.1.0	Arrangement Agreement between Metamaterial Inc. and Torchlight Energy Resources, Inc., dated December 14, 2020	8-K	14-Dec-20
2.1.1	Amendment to Arrangement Agreement dated February 3, 2021	8-K	3-Feb-21
2.1.2	Amendment to Arrangement Agreement dated March 11, 2021	8-K	11-Mar-21
2.1.3	Amendment to Arrangement Agreement dated March 31, 2021	8-K	1-Apr-21
2.1.4	Amendment to Arrangement Agreement dated April 15, 2021	8-K	15-Apr-21
2.1.5	Amendment to Arrangement Agreement dated May 2, 2021	8-K	3-May-21
2.1.6	Amendment to Arrangement Agreement dated June 18, 2021	8-K	21-Jun-21
2.2.0	Arrangement Agreement between Meta Materials Inc. and Nanotech Securities, dated August 4, 2021	10-K	2-March-22
2.3.0	Meta Materials Inc. & Oilco Holdings Inc - 8% Promissory Note Secure - $15 mil loan dated October 1, 2021	10-K/A	24-Mar-23
2.4.0	Stock Pledge Agreement between Gregory McCabe & Meta Materials Inc. dated September 30, 2021	10-K/A	24-Mar-23
3.1.0	Articles of Incorporation	10-K	18-Mar-19
3.1.1	Certificate of Amendment to Articles of Incorporation dated December 10, 2014.	10-Q	15-May-15
3.1.2	Certificate of Amendment to Articles of Incorporation dated September 15, 2015.	10-Q	12-Nov-15
3.1.3	Certificate of Amendment to Articles of Incorporation dated August 18, 2017.	10-Q	9-Nov-18
3.1.4	Amendment to the Articles of Incorporation of Torchlight Energy Resources, Inc., dated June 14, 2021	8-K	16-Jun-21
3.1.5	Certificate of Amendment related to the Reverse Stock Split and Name Change, filed June 25, 2021	8-K	29-Jun-21
3.2.0	Amended and Restated Bylaws	8-K	26-Oct-16
3.3.0	Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Preferred Stock, dated June 14, 2021, as modified by the Certificate of Correction, dated June 15, 2021	8-K	16-Jun-21
3.4.0	Certificate of Designation of Preferences, Rights and Limitations of Series B Special Voting Preferred Stock, dated June 14, 2021	8-K	16-Jun-21
4.1.0	Form of Investor Warrant	10-K	2-March-22
4.2.0	Form of Broker Warrant	10-K	2-March-22
4.3.1	ACOA BDP (2015) - Contract 200804 - Original Document	10-K	2-March-22
4.3.1.1	ACOA BDP (2015) - Contract 200804 - Amendment March 4, 2014	10-K/A	2-May-22
4.3.1.2	ACOA BDP (2015) - Contract 200804 - Amendment November 24, 2014	10-K/A	2-May-22
4.3.1.3

SEC Form 10-K/A filed by Meta Materials Inc. (Amendment)